Tags » Chronic Lymphocytic Leukemia
I know, I haven’t written anything lately, but that doesn’t mean I haven’t been busy. This transplant business is heavy work! (Well it is, but not like bailing hay heavy.) The truth of the matter is that I haven’t had the energy to even think about writing unless I absolutely have to. 507 more words
The FDA announces on July 23rd, that Gilead Sciences’ drug, Zydelig (Idelalisib), receives 3 approvals for blood cancers.
The 1st FDA approval is the “traditional approval” of Gilead Sciences’ FDA Breakthrough Therapy (BTD) Designated product, Zydelig, for relapsed Chronic Lymphocytic Leukemia (CLL). 310 more words
Earlier this afternoon the FDA announced the approval of Zydelig (idelalisib) for patients with relapsed chronic lymphocytic leukemia (CLL). Accelerated approval was also granted for the use of Zydelig in patients with relapsed follicular B-cell non-Hodgkin lymphoma (FL) and relapsed small lymphocytic lymphoma (SLL). 239 more words